{
    "root": "572794a1-b7ec-4327-ab8a-ed6ab8020129",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Skyrizi",
    "value": "20250507",
    "ingredients": [
        {
            "name": "RISANKIZUMAB",
            "code": "90ZX3Q3FR7",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14762"
        },
        {
            "name": "ACETIC ACID",
            "code": "Q40Q9N063P",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15366"
        },
        {
            "name": "POLYSORBATE 20",
            "code": "7T1F30V5YH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53424"
        },
        {
            "name": "SODIUM ACETATE",
            "code": "4550K0SC9B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32954"
        },
        {
            "name": "TREHALOSE",
            "code": "B8WCK70T7I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_27082"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "indications": {
        "text": "skyrizi interleukin-23 antagonist indicated treatment : moderate-to-severe plaque psoriasis adults candidates systemic therapy phototherapy . ( 1.1 ) active psoriatic arthritis adults . ( 1.2 ) moderately severely active crohn 's disease adults . ( 1.3 ) moderately severely active ulcerative colitis adults . ( 1.4 )",
        "doid_entities": [
            {
                "text": "psoriasis (DOID:8893)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8893"
            },
            {
                "text": "psoriatic arthritis (DOID:9008)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9008"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "ulcerative colitis (DOID:8577)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8577"
            },
            {
                "text": "colitis (DOID:0060180)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060180"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe plaque psoriasis",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_247353"
            }
        ]
    },
    "contraindications": {
        "text": "treatment crohn \u2019 disease ulcerative colitis : obtain liver enzymes bilirubin levels prior initiating treatment skyrizi . ( 2.1 , 5.4 ) complete age-appropriate vaccinations recommended current immunization guidelines ( 2.1 , 5.5 ) recommended plaque psoriasis psoriatic arthritis : 150 mg administered subcutaneous injection week 0 , week 4 , every 12 weeks thereafter . ( 2.3 , 2.4 ) patients psoriatic arthritis skyrizi administered alone combination non-biologic disease-modifying antirheumatic drugs ( dmards ) . ( 2.4 ) crohn \u2019 disease : recommended induction 600 mg administered intravenous infusion least one hour week 0 , week 4 , week 8. recommended maintenance 180 mg 360 mg administered subcutaneous injection week 12 , every 8 weeks thereafter . lowest effective maintain therapeutic response . ( 2.6 ) ulcerative colitis : recommended induction 1,200 mg administered intravenous infusion least two hours week 0 , week 4 , week 8. recommended maintenance 180 mg 360 mg administered subcutaneous injection week 12 , every 8 weeks thereafter . lowest effective maintain therapeutic response . ( 2.7 )",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "ulcerative colitis (DOID:8577)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8577"
            },
            {
                "text": "colitis (DOID:0060180)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060180"
            },
            {
                "text": "psoriasis (DOID:8893)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8893"
            },
            {
                "text": "psoriatic arthritis (DOID:9008)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9008"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "non-biologic disease",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_98026"
            }
        ]
    },
    "warningsAndPrecautions": "supplied skyrizi ( risankizumab-rzaa ) injection supplied following strengths : strength pack size ndc subcutaneous injection 150 mg/ml single-dose pen carton 1 0074-2100-01 90 mg/ml single-dose prefilled syringe carton 2 0074-7040-02 carton 4 0074-7042-04 150 mg/ml single-dose prefilled syringe carton 1 0074-1050-01 180 mg/1.2 ml ( 150 mg/ml ) single-dose prefilled cartridge on-body injector kit 0074-1065-01 360 mg/2.4 ml ( 150 mg/ml ) single-dose prefilled cartridge on-body injector kit 0074-1070-01 intravenous infusion 600 mg/10 ml ( 60 mg/ml ) single-dose vial carton 1 0074-5015-01 subcutaneous injection skyrizi 150 mg/ml prefilled syringe prefilled pen contains sterile , preservative-free , colorless yellow , clear slightly opalescent solution . prefilled syringe prefilled pen consists 1 ml glass syringe fixed 27-gauge \u00bd inch needle needle guard . skyrizi 90 mg/ml prefilled syringe sterile , preservative-free , colorless slightly yellow clear slightly opalescent solution . prefilled syringe consists 1 ml glass syringe fixed 29-gauge \u00bd inch needle needle guard . skyrizi 180 mg/1.2 ml ( 150 mg/ml ) cyclic olefin polymer prefilled cartridge septum cap contains sterile , preservative-free , colorless yellow , clear slightly opalescent solution supplied on-body injector device . skyrizi 360 mg/2.4 ml ( 150 mg/ml ) cyclic olefin polymer prefilled cartridge septum cap contains sterile , preservative-free , colorless yellow , clear slightly opalescent solution supplied on-body injector device . intravenous infusion skyrizi 600 mg/10 ml ( 60 mg/ml ) vial contains sterile preservative-free , colorless slightly yellow , clear slightly opalescent solution . glass vial closed stopper blue flip cap . storage handling store refrigerator 36\u00b0f 46\u00b0 f ( 2\u00b0c 8\u00b0c ) . freeze . shake . keep original cartons protect light . made natural rubber latex .",
    "adverseReactions": "skyrizi contraindicated patients history serious hypersensitivity reaction risankizumab-rzaa excipients [ ( 5.1 ) ] .",
    "indications_original": "SKYRIZI is an interleukin-23 antagonist indicated for the treatment of: moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. ( 1.1 ) active psoriatic arthritis in adults. ( 1.2 ) moderately to severely active Crohn's disease in adults. ( 1.3 ) moderately to severely active ulcerative colitis in adults. ( 1.4 )",
    "contraindications_original": "For the treatment of Crohn\u2019s disease and ulcerative colitis: Obtain liver enzymes and bilirubin levels prior to initiating treatment with SKYRIZI. ( 2.1 , 5.4 ) Complete all age-appropriate vaccinations as recommended by current immunization guidelines ( 2.1 , 5.5 ) Recommended Dosage Plaque Psoriasis and Psoriatic Arthritis: 150 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter. ( 2.3 , 2.4 ) In patients with psoriatic arthritis SKYRIZI can be administered alone or in combination with non-biologic disease-modifying antirheumatic drugs (DMARDs). ( 2.4 ) Crohn\u2019s Disease: The recommended induction dosage is 600 mg administered by intravenous infusion over at least one hour at Week 0, Week 4, and Week 8. The recommended maintenance dosage is 180 mg or 360 mg administered by subcutaneous injection at Week 12, and every 8 weeks thereafter. Use the lowest effective dosage to maintain therapeutic response. ( 2.6 ) Ulcerative Colitis: The recommended induction dosage is 1,200 mg administered by intravenous infusion over at least two hours at Week 0, Week 4, and Week 8. The recommended maintenance dosage is 180 mg or 360 mg administered by subcutaneous injection at Week 12, and every 8 weeks thereafter.  Use the lowest effective dosage to maintain therapeutic response. ( 2.7 )",
    "warningsAndPrecautions_original": "How Supplied\n                  \n                  SKYRIZI (risankizumab-rzaa) injection is supplied in the following strengths:\n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                              Strength\n                           \n                           \n                              Pack Size\n                           \n                           \n                              NDC\n                           \n                        \n                        \n                           \n                              Subcutaneous Injection\n                           \n                        \n                        \n                           150 mg/mL single-dose pen\n                           Carton of 1\n                           0074-2100-01\n                        \n                        \n                           90 mg/mL single-dose prefilled syringe\n                           Carton of 2\n                           0074-7040-02\n                        \n                        \n                           \n                           Carton of 4\n                           0074-7042-04\n                        \n                        \n                           150 mg/mL single-dose prefilled syringe\n                           Carton of 1\n                           0074-1050-01\n                        \n                        \n                           180 mg/1.2 mL (150 mg/mL) single-dose prefilled cartridge with on-body injector\n                           Kit\n                           0074-1065-01\n                        \n                        \n                           360 mg/2.4 mL (150 mg/mL) single-dose prefilled cartridge with on-body injector\n                           Kit \n                           0074-1070-01\n                        \n                        \n                           \n                              Intravenous Infusion\n                           \n                        \n                        \n                           600 mg/10 mL (60 mg/mL) single-dose vial\n                           Carton of 1 \n                           0074-5015-01\n                        \n                     \n                  \n                  \n                     Subcutaneous Injection\n                  \n                  SKYRIZI 150 mg/mL prefilled syringe or prefilled pen contains a sterile, preservative-free, colorless to yellow, and clear to slightly opalescent solution. Each prefilled syringe or prefilled pen consists of a 1 mL glass syringe with a fixed 27-gauge \u00bd inch needle with needle guard. \n                  SKYRIZI 90 mg/mL prefilled syringe is a sterile, preservative-free, colorless to slightly yellow and clear to slightly opalescent solution. Each prefilled syringe consists of a 1 mL glass syringe with a fixed 29-gauge \u00bd inch needle with needle guard.\n                  SKYRIZI 180 mg/1.2 mL (150 mg/mL) cyclic olefin polymer prefilled cartridge with a septum and cap contains a sterile, preservative-free, colorless to yellow, and clear to slightly opalescent solution for use with supplied on-body injector administration device.\n                  SKYRIZI 360 mg/2.4 mL (150 mg/mL) cyclic olefin polymer prefilled cartridge with a septum and cap contains a sterile, preservative-free, colorless to yellow, and clear to slightly opalescent solution for use with supplied on-body injector administration device.\n                  \n                     Intravenous Infusion\n                  \n                  SKYRIZI\u00a0600 mg/10 mL (60 mg/mL) vial contains a sterile and preservative-free, colorless to slightly yellow, and clear to slightly opalescent solution.\u00a0Each glass vial is closed with a stopper and blue flip cap.\n                  \n                     Storage and Handling\n                  \n                  \n                     Store in a refrigerator at 36\u00b0F to 46\u00b0 F (2\u00b0C to 8\u00b0C).\n                     \n                     Do not freeze.\n                     \n                     Do not shake.\n                     \n                     Keep in the original cartons to protect from light.\n                     \n                     Not made with natural rubber latex.",
    "adverseReactions_original": "SKYRIZI is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab-rzaa or any of the excipients [see Warnings and Precautions (\n                     \n                        5.1\n                     \n                     )].",
    "drug": [
        {
            "name": "Skyrizi",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14762"
        }
    ]
}